CHASE RANDAL D 4
4 · BIOJECT MEDICAL TECHNOLOGIES INC · Filed Dec 9, 2008
Insider Transaction Report
Form 4
CHASE RANDAL D
Director
Transactions
- Exercise/Conversion
BJCT Common Stock
2008-12-05+19,000→ 73,500 total - Exercise/Conversion
Restricted Stock Unit
2008-12-05−19,000→ 19,000 totalFrom: 2008-12-05→ BJCT Common Stock (19,000 underlying)
Footnotes (3)
- [F1]50% Vesting per June 5, 2008 Board Grant.
- [F2]Each Restricted Stock Unit represents a contingent right to receive one share of BJCT Common Stock.
- [F3]No expiration date.